An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Latest Information Update: 31 Jan 2025
At a glance
- Drugs Itacitinib (Primary)
- Indications Bronchiolitis obliterans
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 10 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 29 Oct 2023 This trial has been completed in Belgium according to According to European Clinical Trials Database record.
- 04 Aug 2023 Planned End Date changed from 19 Jul 2023 to 29 Sep 2023.